W. Carr

TL;DR: Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.

TL;DR: Treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose‐limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo, in this phase 3 trial of oral immunotherapy in children and adolescents who were highly allergic to peanut.

TL;DR: MP29-02 represents a novel therapy that demonstrated superiority to 2 first-line therapies for AR and was observed from the first day of assessment, with improvement in each individual nasal symptom, even in the patients with the most severe disease.

TL;DR: The MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis) as discussed by the authors is a simple system centred around the patient which was devised to fill many of these gaps using Information and Communications Technology (ICT) tools and a clinical decision support system (CDSS) based on the most widely used guideline in allergy and its asthma comorbidity (ARIA 2015 revision).

TL;DR: Targeting purinergic receptor P2X3 with gefapixant at a dose of 50 mg twice daily significantly reduced cough frequency in patients with refractory chronic cough or unexplained chronic cough after 12 weeks of treatment compared with placebo.